Pain management in MPM remains complex due to its multifactorial etiology. Despite progress in the options for treatment in MPM prognosis remains poor. Focus on symptom control is therefore paramount. While effective pain control can be gained through pharmacological treatment, many patients require multiple modalities to achieve symptomatic relief.
Current guidance reinforces the greatest evidence in support of the role of radiotherapy for pain control in MPM. Despite its use, the optimal radiotherapy dose and fraction remains unknown. The SYSTEMS study was key in demonstrating a significant pain response with minimal toxicity with radiotherapy. Now with advances in technology solutions, practical challenges of increasing radiotherapy doses have been achieved. It is hoped that IMRT will allow higher doses of radiation predicted to provide an improvement in analgesic effect and duration. The outcome of the SYSTEMS-2 trial will provide clarity as to this predicted effect of greater doses of radiotherapy on pain control.
At present, both surgical and SACT require further research to focus not only on survival outcomes but also to address the symptomatic impact of treatment. While surgery and SACT may prolong patients’ survival, the consequences of toxicities and complications to patients’ quality of life and pain control requires further investigation. Does undergoing such treatments outweigh the benefit of active symptom control alone? Research to answer this question will continue to allow open communication between patients and clinicians as to the most effective palliative treatment. While interventional procedures, such as cordotomy, demonstrate an exciting opportunity for complex pain control, its availability remains a barrier to widespread use. Guidance highlights cordotomy as playing an important role in MPM for pain management but it remains to be perceived as an option of last resort. Further experience in this field may overcome the challenges to its access and change its role to become an adjuvant at any stage to common analgesic regimens.
Pain is an emotive subject for both patients and their families due to its impact physically and emotionally. MPM is sadly often an aggressive disease with complex pain pathophysiology. Medical professionals strive to achieve the best quality of life for patients through multiple treatment modalities. While pain control in MPM remains to have challenges, it is hoped that research continues to identify solutions to alleviate pain in patients with MPM.
The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.
J. Saunders,1 M. Ashton,1,2 C. Hall,3,4 B. Laird,3,4 N. MacLeod1
1Beatson West of Scotland Cancer Centre, Glasgow G12 0YN, UK; 2Institute of Cancer Sciences, University of Glasgow, UK; 3Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh EH4 2XR, UK; 4St Columba’s Hospice, Edinburgh EH5 3RW, UK
1. British Thoracic Society Standards of Care Committee. BTS statement on malignant mesothelioma in the UK, 2007. Thorax. 2007;62 (Suppl 2): ii1–ii19.
2. McDonald JC, McDonald AD. The epidemiology of mesothelioma in historical context. Eur Respir J. 1996;9(9):1932–1942.
3. Cancer Research UK [Internet]. Mesothelioma statistics. Available from: https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/mesothelioma. Accessed October 8, 2018.
4. Salminen EK, Silvoniemi M, Syrjänen K, Kaasa S, Kloke M, Klepstad P. Opioids in pain management of mesothelioma and lung cancer patients. Acta Oncol. 2013;52(1):30–37.
5. Macleod N, Kelly C, Stobo J, et al. Pain in malignant pleural mesothelioma: a prospective characterization study. Pain Med. 2016;17(11):2119–2126.
6. Baas P, Fennell D, Kerr KM, et al. Malignant pleural mesothelioma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26 (Suppl5):v31–v39.
7. Merskey HBN. Classification of Chronic Pain. 2nd ed. Vol. 1994. Seattle: IASP Press; 1994.
8. Webb JA, Leblanc TW. Evidence-based management of cancer pain. Semin Oncol Nurs. 2018;34(3):215–226.
9. Simmons CPL, Macleod N, Laird BJA. Clinical management of pain in advanced lung cancer. Clin Med Insights Oncol. 2012;6:S8331–S8346.
10. Jackson MB, Pounder D, Price C, Matthews AW, Neville E. Percutaneous cervical cordotomy for the control of pain in patients with pleural mesothelioma. Thorax. 1999;54(3):238–241.
11. Ventafridda V, Tamburini M, Caraceni A, de Conno F, Naldi F. A validation study of the WHO method for cancer pain relief. Cancer. 1987;59(4):850–856.
12. Laird B, Colvin L, Fallon M. Management of cancer pain: basic principles and neuropathic cancer pain. Eur J Cancer. 2008;44(8):1078–1082.
13. Vargas-Schaffer G. Is the WHO analgesic ladder still valid? Twenty-four years of experience. Can Fam Physician. 2010;56(6):514–517, e202–e205.
14. NHS Scotland Palliative Care Guidelines [webpage on the Internet]. Available from: https://www.palliativecareguidelines.scot.nhs.uk/. Accessed February 14, 2019.
15. ClinicalTrials.gov [Internet].University of Edinburgh. Identifier: NCT02706769. A double-blind randomised parallel group trial of paracetamol versus placebo in conjunction with strong opioids for cancer related pain. Available from: https://clinicaltrials.gov/ct2/show/record/NCT02706769. Accessed October 9, 2018.
16. Wiffen PJ, Wee B, Derry S, Bell RF, Moore RA. Opioids for cancer pain – an overview of Cochrane reviews. Cochrane Database Syst Rev. 2017;7:CD012592.
17. Ripamonti CI. Pain management. Ann Oncol. 2012;23(Suppl 10):x294–x301.
18. Wickham RJ. Cancer pain management: comprehensive assessment and nonopioid analgesics, part 1. J Adv Pract Oncol. 2017;8(5):475–490.
19. Schmidt-Hansen M, Bennett MI, Arnold S, Bromham N, Hilgart JS. Oxycodone for cancer-related pain. Cochrane Database Syst Rev. 2015;2:Cd003870.
20. Teoh PJ, Camm CF. NICE opioids in palliative care (clinical guideline 140) – a guideline summary. Ann Med Surg. 2012;1:44–48.
21. Bennett MI. Effectiveness of antiepileptic or antidepressant drugs when added to opioids for cancer pain: systematic review. Palliat Med. 2011;25(5):553–559.
22. Stevens CW, Forster KM, Smythe WR, Rice D. Radiotherapy for mesothelioma. Hematol Oncol Clin North Am. 2005;19(6):1099–1115, vii.
23. Boutin C, Rey F, Viallat JR. Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma. A randomized trial of local radiotherapy. Chest. 1995;108(3):754–758.
24. Bydder S, Phillips M, Joseph DJ, et al. A randomised trial of single-dose radiotherapy to prevent procedure tract metastasis by malignant mesothelioma. Br J Cancer. 2004;91(1):9–10.
25. O’Rourke N, Garcia JC, Paul J, Lawless C, McMenemin R, Hill J. A randomised controlled trial of intervention site radiotherapy in malignant pleural mesothelioma. Radiother Oncol. 2007;84(1):18–22.
26. Bayman N, Ardron D, Ashcroft L, et al. Protocol for pit: a phase III trial of prophylactic irradiation of tracts in patients with malignant pleural mesothelioma following invasive chest wall intervention. BMJ Open. 2016;6(1):e010589.
27. Clive AO, Taylor H, Dobson L, et al. Prophylactic radiotherapy for the prevention of procedure-tract metastases after surgical and large-bore pleural procedures in malignant pleural mesothelioma (smart): a multicentre, open-label, phase 3, randomised controlled trial. Lancet Oncol. 2016;17(8):1094–1104.
28. Kindler HL, Ismaila N, Armato SG, et al. Treatment of malignant pleural mesothelioma: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2018;36(13):1343–1373.
29. Macleod N, Price A, O’Rourke N, Fallon M, Laird B. Radiotherapy for the treatment of pain in malignant pleural mesothelioma: a systematic review. Lung Cancer. 2014;83(2):133–138.
30. Macleod N, Chalmers A, O’Rourke N, et al. Is radiotherapy useful for treating pain in mesothelioma? A phase II trial. J Thorac Oncol. 2015;10(6):944–950.
31. Ashton M, O’Rourke N, Macleod N, et al. SYSTEMS-2: a randomised phase II study of radiotherapy dose escalation for pain control in malignant pleural mesothelioma. Clin Transl Radiat Oncol. 2018;8:45–49.
32. Parker C, Neville E. Lung cancer * 8: management of malignant mesothelioma. Thorax. 2003;58(9):809–813.
33. Eisenberg EMF, Birkhahm J, Paladín A, Varrassi G. Time to modify the WHO analgesic leader? Pain Clin Update. 2005;13(5):1–4.
34. Department of health. Clinical programmes: Cancer. Mesothelioma framework. Published 27.02.2007. Available from: https://webarchive.nationalarchives.gov.uk/20130124034731/http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/documents/digitalasset/dh_072347.pdf. Accessed February 14, 2019.
35. France BD, Lewis RA, Sharma ML, Poolman M. Cordotomy in mesothelioma-related pain: a systematic review. BMJ Support Palliat Care. 2014;4(1):19–29.
36. Fallon M, Giusti R, Aielli F, et al. Management of cancer pain in adult patients: ESMO clinical practice guidelines. Ann Oncol. 2018;29(Suppl 4):iv166–iv191.
37. Feizerfan A, Antrobus JHL. Role of percutaneous cervical cordotomy in cancer pain management. Cont Educ Anaesth Crit Care Pain. 2014;14(1):23–26.
38. Hochberg U, Elgueta MF, Perez J. Interventional analgesic management of lung cancer pain. Front Oncol. 2017;7(12):17.
39. Wong FC, Lee TW, Yuen KK, Lo SH, Sze WK, Tung SY. Intercostal nerve blockade for cancer pain: effectiveness and selection of patients. Hong Kong Med J. 2007;13(4):266–270.
40. Matchett G. Intercostal nerve block and Neurolysis for intractable cancer pain. J Pain Palliat Care Pharmacother. 2016;30(2):114–117.
41. Ahmed A, Bhatnagar S, Khurana D, Joshi S, Thulkar S. Ultrasound-guided radiofrequency treatment of intercostal nerves for the prevention of incidental pain arising due to rib metastasis. Am J Hosp Palliat Care. 2017;34(2):115–124.
42. Ju H, Feng Y, Yang BX, Wang J. Comparison of epidural analgesia and intercostal nerve cryoanalgesia for post-thoracotomy pain control. Eur J Pain. 2008;12(3):378–384.
43. Ambrogi V, Mineo D, Gatti A, Pompeo E, Mineo TC. Symptomatic and quality of life changes after extrapleural pneumonectomy for malignant pleural mesothelioma. J Surg Oncol. 2009;100(3):199–204.
44. Cao C, Tian D, Park J, Allan J, Pataky KA, Yan TD. A systematic review and meta-analysis of surgical treatments for malignant pleural mesothelioma. Lung Cancer. 2014;83(2):240–245.
45. Treasure T, Lang-Lazdunski L, Waller D, et al. Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the mesothelioma and radical surgery (MARs) randomised feasibility study. Lancet Oncol. 2011;12(8):763–772.
46. Weder W, Stahel RA, Baas P, et al. The Mars feasibility trial: conclusions not supported by data. Lancet Oncol. 2011;12(12):1093–1094.
47. Lang-Lazdunski L. Surgery for malignant pleural mesothelioma: why, when and what? Lung Cancer. 2014;84(2):103–109.
48. Flores RM, Pass HI, Seshan VE, et al. Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients. J Thorac Cardiovasc Surg. 2008;135(3):620–626, 626.e1–3.
49. ClinicalTrials.gov [Internet]. Royal brompton & harefield NHS foundation trustidentifier: NCT02040272. Mesothelioma and radical surgery 2: a multicentre randomised trial comparing (extended) pleurectomy decortication versus no (extended) pleurectomy decortication for patients with malignant pleural mesothelioma (mars 2). Available from: https://clinicaltrials.gov/ct2/show/record/NCT02040272. Accessed October 8, 2018.
50. Ricciardi S, Cardillo G, Zirafa CC, et al. Surgery for malignant pleural mesothelioma: an international guidelines review. J Thorac Dis. 2018;10(Suppl 2):S285–S292.
51. Rintoul RC, Ritchie AJ, Edwards JG, et al. Efficacy and cost of video-assisted thoracoscopic partial pleurectomy versus talc pleurodesis in patients with malignant pleural mesothelioma (MesoVATS): an open-label, randomised, controlled trial. Lancet. 2014;384(9948):1118–1127.
52. Woolhouse I, Bishop L, Darlison L, et al. British Thoracic Society guideline for the investigation and management of malignant pleural mesothelioma. Thorax. 2018;73(Suppl 1):i1–i30.
53. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21(14):2636–2644.
54. Gralla RJ, Hollen PJ, Am L, Liepa AM, et al. Improving quality of life in patients with malignant pleural mesothelioma: Results of the randomized pemetrexed and cisplatin vs. cisplatin trial using the LCSS-meso instrument. Proc Am Soc Clin Oncol. 2003;22:abstr 2496.
55. Zalcman G, Mazieres J, Margery J, et al. Bevacizumab for newly diagnosed pleural mesothelioma in the mesothelioma Avastin cisplatin pemetrexed study (MAPs): a randomised, controlled, open-label, phase 3 trial. Lancet. 2016;387(10026):1405–1414.
56. Westeel V, Eberst G, Anota A, et al. Impact on health-related quality of life of the addition of bevacizumab to cisplatin-pemetrexed in malignant pleural mesothelioma in the maps phase III trial. J Clin Oncol. 2018;36(Suppl 15):8505–8505.
57. Cinausero M, Rihawi K, Sperandi F, Melotti B, Ardizzoni A. Chemotherapy treatment in malignant pleural mesothelioma: a difficult history. J Thorac Dis. 2018;10(Suppl 2):S304–S310.
58. Santoro A, O’Brien ME, Stahel RA, et al. Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma: results of the International expanded access program. J Thorac Oncol. 2008;3(7):756–763.
59. Muers MF, Stephens RJ, Fisher P, et al. Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial. Lancet. 2008;371(9625):1685–1694.
60. Bibby AC, Maskell NA. Current treatments and trials in malignant pleural mesothelioma. Clin Respir J. 2018;12(7):2161–2169.
61. Alley EW, Lopez J, Santoro A, et al. Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1B trial. Lancet Oncol. 2017;18(5):623–630.
62. ClinicalTrials.gov [Internet]. European Thoracic Oncology Platform. Identifier: NCT02991482. PembROlizuMab Immunotherapy Versus Standard Chemotherapy for Advanced prE-treated Malignant Pleural Mesothelioma (PROMISE-meso). Available from:https://clinicaltrials.gov/ct2/show/NCT02991482. Accessed October 8, 2018.
63. Zalcman G, Mazieres J, Greillier L, et al. Second or 3rd line nivolumab versus nivolumab plus ipilimumab in malignant pleural mesothelioma patients: updated results of the IFCT-1501 MAPS2 randomized phase 2 trial. In: 2017 ESMO Congress. Abstract LBA58_PR; September 10, 2017.
Source: Lung Cancer: Targets and Therapy
Originally published April 2, 2019.
READ FULL ARTICLE From Dovepress